Study summary · research use only
Cerebrolysin: a multi-target drug for recovery after stroke
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This narrative review discusses Cerebrolysin, a neuropeptide preparation described as having neurotrophic properties, in the context of recovery after stroke. The abstract reports that in human clinical trials, results with Cerebrolysin were often studied in mildly affected stroke populations, and subgroup analyses of more severely affected patients showed a stronger effect on recovery measures, with effect size reported to increase with stroke severity. Other controlled studies described combined use of Cerebrolysin with thrombolysis. The review also discusses testing of Cerebrolysin for neuroprotection and neurorecovery in patients with moderate to severe strokes, and reports a benefit for functional recovery when combined with neurorehabilitation compared with neurorehabilitation alone, noting this supports planning of a more rigorous future study design.
Abstract
Cerebrolysin is a neuropeptide preparation with neurotrophic effects and promotes recovery after brain injury. Its preclinical profile promises wide applications due to its multi-target effects. Currently, Cerebrolysin is used for treatment of cerebral ischemia and neurodegeneration. Areas covered: In stroke, earlier clinical trials with Cerebrolysin were performed mostly in mildly affected stroke populations, which usually have a favorable prognosis. Due to this selection, a floor or ceiling effect of recovery measures in the mild cases may have prevented to show a clear benefit between treatment groups. In contrast, subgroup analyses of more severely affected patients reveal a strikingly positive effect for enhanced recovery. Based on the findings from several studies, it became evident that the effect size of Cerebrolysin was increasing with stroke severity. Other controlled studies showed that Cerebrolysin can be safely used in combination with thrombolysis. More recently, Cerebrolysin has been tested not only for neuroprotection but also for its neurorecovery potential and also showed efficacy in patients with moderate to severe strokes. Expert commentary: Cerebrolysin shows a benefit mostly in moderate to severe ischemic stroke patients and an overall significant effect for functional recovery when combined with neurorehabilitation versus neurorehabilitation alone. This gives lead to the planning of a more rigorous study design in the future.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.